Aptamer Group
plc
("Aptamer", the "Company" or the "Group")
Commercial Trading
Update
Aptamer Group plc (AIM: APTA), the
developer of novel Optimer® binders to enable innovation
in the life sciences industry, is pleased to provide an update on
contracts signed since its financial year ended 30 June
2024.
Aptamer has secured new contracts
worth up to £471,000 continuing the positive commercial traction
achieved during the last quarter of the previous financial year.
These contracts include multiple agreements, including two from top
20 and one from a top 5 global pharmaceutical companies, totalling
up to £340,000. These projects are aimed at developing Optimers as
critical reagents to support active clinical development programmes
and facilitate the analysis of novel therapeutics.
A significant proportion of these
deals involve repeat customers who are advancing Aptamer's binders
within their internal pipelines, with some signalling intent for
long-term licensing revenues. This ongoing traction highlights
Aptamer's role in supporting key industry players and reinforces
our position as a key player in the market.
These new contracts illustrate
Aptamer's increasing commercial traction and the Group's ability to
secure repeat business from top pharmaceutical companies. Aptamer
now has booked revenue contracts of up to c. £1.2m to recognise
throughout FY25 (Jun 25 year-end) and an increased sales pipeline
from £2.1m in July 2024 to £4.0m as of today.
Dr
Arron Tolley, Chief Executive Officer of Aptamer Group
said: "Following the fundraise in
August 2024, I am pleased to report that the sustained focus of our
commercial team continues to bear fruit. We are advancing steadily
towards our revenue and potential licensing goals for FY 25 with
the best part of 7 months left in the financial year. Revenue
generation and increased income from licensing form a pivotal
component of the Group's strategy to deliver shareholder value and
I look forward to updating you on future contracts and key project
updates."
- Ends -
For
further information, please contact:
|
Aptamer Group plc
Arron Tolley, Chief Executive
Officer
|
+44 (0) 1904 217
404
|
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368
3550
|
|
Turner Pope Investments (TPI) Limited -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657
0050
|
|
Northstar Communications Limited - Investor
Relations
Sarah Hollins
|
+44 (0) 113 730 3896
|
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary
Optimer® platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers.
Optimer binders are oligonucleotide
affinity ligands that can function as an antibody alternative. The
global affinity ligand market is currently worth over $170
billion.
Aptamer has successfully delivered
projects for a range of global pharma companies, diagnostic
development companies, and research institutes, covering multiple
application areas with the objective of establishing
royalty-bearing licenses.